How it works
We monitor your competitive landscape, analyze what developments mean for your marketing strategy, and recommend what to do next. Delivered to your inbox, without another platform to manage.
We track developments across your competitive landscape and filter out the noise, so you can focus on changes that could affect your products, customers, and markets.
From product launches and messaging changes to clinical evidence, partnerships, regulatory developments, and market expansion.
A product launch, a new clinical claim, or a shift in messaging rarely tells the whole story.
We connect developments over time, assess them in the context of your market, and identify what they could mean for your competitive position.
Know when to sharpen your differentiation, rethink a claim, adjust a campaign, or strengthen your sales arguments.
Get prioritized recommendations grounded in evidence, including where action is warranted, what deserves further investigation, and when to stay the course.
We combine automated and manual monitoring across public sources. Findings include source references and confidence assessments.
Public sources across five areas.
Not another list of competitor news. What changed, what it means, and your next moves.
Weekly brief · Website messaging
Real-world example*RivalKite · Intelligence team
to Your team
Abbott Volt vs Boston Scientific FARAPULSE
How each opens its US page for healthcare professionals.
Abbott · cardiovascular.abbott · Volt PFA System
Leads with the benefit
“Fewer applications and total control.” The evidence sits in the side navigation.
Boston Scientific · bostonscientific.com · FARAPULSE PFA Platform
Leads with the evidence
A “Clinical data” button in the hero. A trial announcement competes with the core message.
Our take: Abbott says more clearly why to consider Volt; Boston Scientific makes the evidence easier to find. Neither opening pairs a specific benefit with its proof.
Your next moves
Priority alert · Earnings call
Real-world example*RivalKite · Intelligence team
to Your team
Boston Scientific expects to keep losing PFA share until early 2028.
On the Q3 call, management said EP sales fell 5%: down 8% in the US, up 2% internationally. It expects continued erosion of its PFA share until FARAWAVE Ultra launches, now expected in early 2028.
Why it matters: Abbott's acceleration is clear. How much comes from Boston Scientific, and what it means for your accounts, is not yet known.
Earlier alerts
A cyberattack cost about $150 million of revenue.
The outage cost is company-wide, not specific to electrophysiology, so it blurs how much of the 5% EP decline comes from competition.
MedTech Dive report on the call
Electrophysiology sales up 15.5% on a comparable basis.
Q3 EP sales of $873 million, up 15.0% as reported. The CEO credited the new Volt PFA catheter.
Abbott results filingAbbott CEO commentary
Monthly review · October 2026
Real-world example*RivalKite · Intelligence team
to Your team
October 2026: PFA messaging and competition
What changed in October, and where to act, investigate or stay the course.
Sources
Continuous intelligence delivered by email, in a format your team can use.
Every week
A concise competitive intelligence brief focused on your competitors, markets, and agreed business priorities.
Each brief covers
Findings include public source links and confidence assessments.
Every month
A strategic review connects recent competitor activity and identifies patterns, threats, and opportunities that individual updates may miss.
We assess what the developments mean for your positioning, differentiation, messaging, supporting evidence, sales enablement, campaigns, and go-to-market priorities.
Priority alerts
Some developments shouldn’t wait for the next scheduled brief.
Receive timely alerts on significant competitive moves, such as major product launches, regulatory approvals, acquisitions, and strategic partnerships.
Alerts are event-driven, not sent on a fixed schedule.
Many competitive intelligence platforms can monitor competitors, detect developments and analyze information.
RivalKite provides a managed service with analysis tailored to your specific products, markets, competitive positioning, and commercial priorities.
We combine automated and manual monitoring with senior MedTech product marketing expertise to evaluate what developments could mean for your business and recommend practical next steps.
You receive the analysis and recommendations directly, without needing to manage another platform or build an internal competitive intelligence process.
Our briefs highlight relevant competitor developments, explain their potential significance, assess the implications for your competitive position, and recommend actions or areas for further investigation.
Our aim is to help your team distinguish meaningful changes from routine competitor activity.
Weekly briefs, monthly strategic reviews, and priority alerts are delivered by email.
There’s no additional software platform to learn or manage.
No. RivalKite provides market intelligence and product marketing analysis to support commercial decision-making.
Our recommendations are not regulatory, legal, or clinical advice. Claims and marketing materials should be reviewed by your regulatory and legal teams before use.
Tell us who you compete with and what you want to understand. We'll show you what RivalKite finds.
No commitment. No sales call required.